MX2017013384A - Composiciones que comprenden adamts13 para el uso en metodos para la recanalizacion de los vasos sanguineos ocluidos en un infarto. - Google Patents
Composiciones que comprenden adamts13 para el uso en metodos para la recanalizacion de los vasos sanguineos ocluidos en un infarto.Info
- Publication number
- MX2017013384A MX2017013384A MX2017013384A MX2017013384A MX2017013384A MX 2017013384 A MX2017013384 A MX 2017013384A MX 2017013384 A MX2017013384 A MX 2017013384A MX 2017013384 A MX2017013384 A MX 2017013384A MX 2017013384 A MX2017013384 A MX 2017013384A
- Authority
- MX
- Mexico
- Prior art keywords
- infarction
- methods
- blood vessels
- adamts13
- recanalization
- Prior art date
Links
- 206010061216 Infarction Diseases 0.000 title abstract 4
- 210000004204 blood vessel Anatomy 0.000 title abstract 4
- 230000007574 infarction Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000043853 ADAMTS13 Human genes 0.000 abstract 2
- 108091005670 ADAMTS13 Proteins 0.000 abstract 2
- 238000001514 detection method Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se relaciona con métodos para la recanalización de vasos sanguíneos ocluidos en un paciente que tiene un infarto. El método incluye una etapa de administrar al paciente una cantidad terapéuticamente efectiva de la proteína ADAMTS13 aislada a dosificaciones particulares e intervalos de tiempo después de la detección del infarto. Como se describe en la presente, ADAMTS13 recanaliza ventajosamente los vasos sanguíneos ocluidos y reduce el tamaño del infarto, aun cuando se administra un periodo prolongado después de la oclusión estable. Por lo tanto, tales métodos y composiciones son útiles para el tratamiento de infartos causados por la oclusión de vasos sanguíneos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562166586P | 2015-05-26 | 2015-05-26 | |
| PCT/US2016/034353 WO2016191565A1 (en) | 2015-05-26 | 2016-05-26 | Compositions comprising adamts13 for use in methods for the recanalization of occluded blood vessels in an infarction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013384A true MX2017013384A (es) | 2017-12-07 |
Family
ID=53784248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013384A MX2017013384A (es) | 2015-05-26 | 2016-05-26 | Composiciones que comprenden adamts13 para el uso en metodos para la recanalizacion de los vasos sanguineos ocluidos en un infarto. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180110842A1 (es) |
| EP (1) | EP3302533A1 (es) |
| JP (2) | JP6877356B2 (es) |
| KR (1) | KR20180006376A (es) |
| CN (1) | CN107635577A (es) |
| AU (2) | AU2016268389A1 (es) |
| BR (1) | BR112017025142A2 (es) |
| CA (1) | CA2979940A1 (es) |
| EA (1) | EA201792130A1 (es) |
| GB (1) | GB201510870D0 (es) |
| HK (1) | HK1249863A1 (es) |
| MX (1) | MX2017013384A (es) |
| WO (1) | WO2016191565A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021248679A1 (en) | 2020-04-02 | 2022-10-27 | Takeda Pharmaceutical Company Limited | ADAMTS13 variant, compositions, and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009539757A (ja) * | 2006-06-16 | 2009-11-19 | バクスター・インターナショナル・インコーポレイテッド | 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物 |
| JP5254973B2 (ja) * | 2007-06-22 | 2013-08-07 | 一般財団法人化学及血清療法研究所 | 新規ａｄａｍｔｓ−１３改変体 |
| AU2009246603B8 (en) * | 2008-05-12 | 2015-08-13 | Children's Medical Center Corporation | von Willebrand Factor (VWF) inhibitors for treatment or prevention of infarction |
| KR20210054598A (ko) * | 2009-09-21 | 2021-05-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제 |
| CN103566362B (zh) * | 2012-07-21 | 2015-07-29 | 复旦大学 | 重组adamts13在制备脑出血药物中的用途 |
| AU2013203062C1 (en) * | 2013-03-15 | 2018-06-28 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of adamts13 |
-
2015
- 2015-06-19 GB GBGB1510870.7A patent/GB201510870D0/en not_active Ceased
-
2016
- 2016-05-26 CN CN201680026628.6A patent/CN107635577A/zh active Pending
- 2016-05-26 KR KR1020177031775A patent/KR20180006376A/ko not_active Withdrawn
- 2016-05-26 AU AU2016268389A patent/AU2016268389A1/en not_active Abandoned
- 2016-05-26 MX MX2017013384A patent/MX2017013384A/es unknown
- 2016-05-26 EP EP16729425.5A patent/EP3302533A1/en not_active Withdrawn
- 2016-05-26 US US15/572,681 patent/US20180110842A1/en not_active Abandoned
- 2016-05-26 JP JP2017552120A patent/JP6877356B2/ja not_active Expired - Fee Related
- 2016-05-26 HK HK18109356.9A patent/HK1249863A1/zh unknown
- 2016-05-26 EA EA201792130A patent/EA201792130A1/ru unknown
- 2016-05-26 WO PCT/US2016/034353 patent/WO2016191565A1/en not_active Ceased
- 2016-05-26 CA CA2979940A patent/CA2979940A1/en not_active Abandoned
- 2016-05-26 BR BR112017025142A patent/BR112017025142A2/pt not_active IP Right Cessation
-
2019
- 2019-10-03 US US16/592,554 patent/US20210128701A1/en not_active Abandoned
-
2021
- 2021-04-27 JP JP2021074695A patent/JP2021138699A/ja active Pending
-
2022
- 2022-05-26 AU AU2022203572A patent/AU2022203572A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017025142A2 (pt) | 2018-08-07 |
| GB201510870D0 (en) | 2015-08-05 |
| US20180110842A1 (en) | 2018-04-26 |
| AU2016268389A1 (en) | 2017-09-28 |
| US20210128701A1 (en) | 2021-05-06 |
| WO2016191565A1 (en) | 2016-12-01 |
| CN107635577A (zh) | 2018-01-26 |
| AU2022203572A1 (en) | 2022-06-16 |
| JP2018516855A (ja) | 2018-06-28 |
| EP3302533A1 (en) | 2018-04-11 |
| KR20180006376A (ko) | 2018-01-17 |
| JP6877356B2 (ja) | 2021-05-26 |
| JP2021138699A (ja) | 2021-09-16 |
| EA201792130A1 (ru) | 2018-04-30 |
| HK1249863A1 (zh) | 2018-11-16 |
| CA2979940A1 (en) | 2016-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502251A1 (en) | Formulations of an lsd1 inhibitor | |
| WO2016070166A3 (en) | Messenger una molecules and uses thereof | |
| WO2015123423A3 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
| MY196631A (en) | Antibody Agents Specific for Human Cd19 and uses Thereof | |
| ZA201700196B (en) | Methods for treating high cardiovascular risk patients with hypercholesterolemia | |
| WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| PH12015502539A1 (en) | Cenicriviroc compositions and methods of making and using the same | |
| EA201591752A1 (ru) | Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы | |
| PH12016502430B1 (en) | Method for decreasing immunogenicity of protein and peptide | |
| EP4279128A3 (en) | Novel antibody binding to tfpi and composition comprising the same | |
| MX2023005014A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
| CA3010708A1 (en) | Methods of administering hepcidin | |
| CA3010788A1 (en) | Methods of administering vasopressors | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| AU2018256669A1 (en) | Combination therapy | |
| NZ726132A (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MX373272B (es) | Terapia de combinacion. | |
| HK1246685A1 (zh) | 治疗或预防具有心肌梗塞病史的患者的动脉粥样硬化血栓形成事件的方法 | |
| WO2015156674A3 (en) | Method for treating cancer | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX2017014776A (es) | Combinacion farmaceutica de everolimus con dactolisib. | |
| HK1249863A1 (zh) | 包含adamts13的组合物在使梗塞中阻塞的血管再通的方法中的应用 | |
| IN2013MU03428A (es) | ||
| WO2015200768A3 (en) | Pharmacologic treatments of menière's disease | |
| PH12017501918A1 (en) | Multi-peptide composition |